CEL-SCI Conducts Meeting Of North American Clinical Centers To Support Success Of Its Phase 3 Cancer Trial With Multikine

VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE MKT: CVM) announced today that it has held the Investigator Meeting for the North American clinical investigators participating in the ongoing international Phase III clinical trial of its investigational cancer immunotherapy treatment Multikine* (Leukocyte Interleukin, Inj.). Investigators from 14 clinical centers in Canada and the U.S. who are participating in the Phase III clinical trial for head and neck cancer were in attendance. The Investigator Meeting for the 56 clinical centers in Europe that are participating in the study was held in October 2013. A total of approximately 880 patients are expected to be enrolled in the Phase III study. Patients are also being enrolled in the Phase III study in Israel and Taiwan where CEL-SCI's partners Teva Pharmaceuticals and Orient Europharma are based.

Help employers find you! Check out all the jobs and post your resume.